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Historically, the incidence rates of breast cancer in China, Japan
and some other Asian countries have been substantially lower than
those in the United States and Europe (Parkin et al, 1997).
Ecological and migration studies have suggested that the marked
international variation in breast cancer incidence largely due to
environmental factors, such as dietary habits (Henderson et al,
1996). Soyfoods, consumed in high quantities by Asian women,
are one possible explanation for this difference. Soyfoods and
some of their constituents have been implicated in numerous in
vitro and animal studies as being potentially protective against
breast and perhaps other hormone-related cancers (Adlercreutz
and Mazur, 1997; Messina et al, 1997). Analytic epidemiologic
studies on soyfood intake and breast cancer risk, however, have
been few and inconsistent (Hirohata et al, 1985; Hirayama 1990;
Lee et al, 1991, 1992; Hirose et al, 1995; Yuan et al, 1995;
Greenstein et al, 1996; Wu et al, 1996, 1998; Witte et al, 1997;
Key et al, 1999). Part of the inconsistency may be due to errors in
exposure assessment and confounding. Intakes of soyfood in the
United States are low, limiting the ability to conduct informative
observational studies (Wu et al, 1998). 
Soyfoods are the major sources of isoflavones, a group of
phytoestrogens showing both weak oestrogenic and antioestro-
genic activities. These phytochemicals have been shown to
compete with endogenous oestrogens for oestrogen receptors in
many in vitro and in vivo systems (Adlercreutz and Mazur, 1997).
High soy consumption has been shown in some studies to decrease
ovarian hormones (Lu et al, 2000) and increase plasma sex
hormone-binding globulin (SHBG) (Duncan et al, 1999; Pino et al,
2000). Thus the potential cancer-inhibitory effect of soyfood may
be more evident for breast cancers expressing oestrogen receptor.
In addition to an anti-oestrogenic effect, several recent animal
studies showed that soy proteins improve glucose tolerance and
insulin sensitivity (Wagner et al, 1997). Insulin resistance has been
linked to an elevated risk of breast cancer (Bruning et al, 1992;
Yang et al, 2001). Body weight, measured using body mass index
(BMI), and central obesity measured using the waist-to-hip ratio
(WHR) are associated with an elevated level of blood insulin and a
reduced level of SHBG (and thus an elevated level of oestrogen
bioavailability) (Pasquali et al, 1987; Seidell, 2000). BMI is also
positively associated with oestrogen levels among postmenopausal
women (Siiteri, 1987). A protective effect of soyfood intake may
therefore be more pronounced among women with a high BMI
and/or WHR. To evaluate the association of soyfood intake with
breast cancer risk and potential modifying effects of BMI, WHR
and ER/PR status, we analysed data from the Shanghai Breast
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Summary We evaluated the association of soyfood intake and breast cancer risk in a population-based case–control study among Chinese
women in Shanghai. Included in the study were 1459 cases and 1556 age-matched controls, with respective response rates of 91.1% and
90.3%. Usual soyfood intake was assessed using a food frequency questionnaire (FFQ). Separate analyses were performed for all subjects
and for the subset who reported no recent change in soyfood intake. The intake levels of soyfoods among women in Shanghai are high, with
96.6% women reporting soyfood consumption at least once a week. A statistically non-significant reduced risk (odds ratio (OR) = 0.78 95% CI
= 0.52–1.16) of breast cancer was observed among those who reported eating soyfood at least once a week. Compared to those in the lowest
decile intake group, women in the highest decile intake group had a 30% reduced risk of breast cancer (OR = 0.66, 95% CI = 0.46–0.95), but
no monotonic dose–response relation was observed (P for trend, 0.28). Stratified analyses showed that the inverse association was restricted
primarily among women who had a high body mass index (BMI), with an adjusted OR of 0.30 (95% CI = 0.10–0.94) observed for the highest
intake group. The reduction in risk was stronger for breast cancer positive for both oestrogen receptor (ER) and progesterone receptor (PR)
(OR = 0.44, 95% CI = 0.25–0.78) than those with other ER/PR status. More pronounced inverse associations were observed in analyses
among those who reported no recent change in soyfood intake than those conducted in all subjects. A dose–response relation between
soyfood intake and breast cancer risk was observed in this subset of women (P for trend, 0.02), with an OR of 0.46 (95%CI = 0.28–0.75) for
those in the highest decile intake group. No clear monotonic dose–response relation was found between soyfood intake and breast cancer
risk among regular soy eaters, but nevertheless the results suggest that regular soyfood consumption may reduce the risk of breast cancer,
particularly for those positive for ER and PR; the effect may be modified by body mass index. © 2001 Cancer Research Campaign
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Cancer Study, a population-based case–control study of breast
cancer among Chinese women in Shanghai during 1996–1998. 
METHODS 
The Shanghai Breast Cancer Study was designed to recruit all
women aged 25 to 64 newly diagnosed with breast cancer from
August 1996 to March 1998. All study subjects were permanent
residents of urban Shanghai with no prior history of cancer. The
ethical aspects of the study were approved by relevant institutional
review boards. Through a rapid case-ascertainment system,
supplemented by the population-based Shanghai Cancer Registry,
1602 eligible breast cancer cases were identified during the study
period, and in-person interviews were completed for 1459
(91.1%). The major reasons for non-participation were refusal
(109 cases, 6.8%), death prior to interview (17 cases, 1.1%), and
inability to locate (17 cases, 1.1%). 2 senior pathologists reviewed
all slides to confirm all cancer diagnoses. Detailed information on
cancer diagnosis and treatment including oestrogen (ER) and
progesterone (PR) status was abstracted from medical charts. The
information on ER/PR status was obtained for 956 of the 1459
breast cancer cases. Of these, 52.7% were ER+/PR+; 11.2%,
ER+/PR2; 10.6%, ER2/PR+; and 25.5%, ER2/PR2. 
The Shanghai Resident Registry, which keeps records for all
permanent residents in urban Shanghai, was used to select controls
randomly from female residents, frequency-matched to cases by
age (5-year interval). The number of controls in each age-specific
stratum was determined in advance according to the age distribu-
tion of the incident breast cancer cases reported to the Shanghai
Cancer Registry from 1990–1993. Only women who lived at the
address identified during the study period were considered to be
eligible for the study. In-person interviews were completed for
1556 (90.3%) of the 1724 eligible controls identified. Reasons for
non-participation included refusal (166 controls, 9.6%), and death
prior to the interview (2 controls, 0.1%). 
All study participants were interviewed in person by trained
interviewers and measured for weight, circumferences of waist
and hip, and sitting and standing heights. A structured question-
naire was used to elicit detailed information on demographic
factors, menstrual and reproductive history, hormone use, dietary
habits, prior disease history, physical activity, tobacco and alcohol
use, weight and family history of cancer. Information on usual
dietary intake was collected using a comprehensive quantitative
food-frequency questionnaire (FFQ), including questions usual
consumption of soymilk, tofu, dry soybeans, soy products other
than tofu, fresh soybeans and soybean sprouts. These food items
were shown to account for over 90% of soyfoods consumed in
Shanghai in a recent 24-hour dietary survey (Satia et al, 1999). 
During the interview, each study participant was first asked how
frequently she consumed a specific soyfood or group of soyfoods
(per day, week, month, year or never), followed by a question on
how many lians (= 50 grams) she ate the food(s) per unit of time
(day, week, month, or year) in the previous 5-year period, ignoring
any recent changes. For fresh soybeans, subjects were asked to
describe their consumption when the food was available on the
market. 7 months after initiation of the study, a supplementary
survey was added, in which all subjects were asked whether their
intake levels of selected foods (including soyfoods) 1 week before
interview were similar, increased or decreased compared to their
usual intake levels of these foods in the past 5 years. The supple-
mentary survey was completed for 1104 cases and 1232 controls.
65.8% of cases and 82.5% of controls reported no change in
soyfood intake; 16.9% of cases versus 7.2% of controls reported
an increase and 16.8% of cases versus 10.0% of controls reported a
decrease in soyfood intake. 
Total soyfood consumption was measured by summing the soy
protein derived from soyfoods. Soy protein intake was computed
based on the Chinese Food Composition Table (Chinese Academy
of Medical Sciences, 1991). Total isoflavone intake was also
calculated using the published data (Chen et al, 1999). Soy protein
and soy isoflavones are better measurements of total soyfood
intake because individuals who rarely eat one type of soyfood
might eat other types frequently and soy protein concentrations
vary widely across different soyfoods. Because results from our
analyses showed similar patterns using soy protein and soy
isoflavone intakes and some recent studies suggested that soy, but
not isoflavones, may be more important in reducing breast cancer
risk (Constantinou et al, 2000), we present results only on soy
protein. Partial sum-of-squares in the multivariate linear regres-
sion model was used to estimate how each individual soyfood
accounted for the percentage of between-subject variation of total
soy protein. Subjects who ate soyfoods less often than once per
week were used as the reference in our primary analyses and we
classified the regular soy consumers into 4 groups based on the
quartile distributions among controls. Analyses were also
conducted based on decile distributions of soyfood intake among
controls. 
Unconditional logistic regression models were used to obtain
maximum likelihood estimates of the odds ratios (OR) and their
95% confidence intervals (95% CI), after adjusting for potential
confounding variables (Breslow and Day, 1980). Age was
included as a continuous variable throughout, and categorical vari-
ables were treated as dummy variables in the model. Testing for
linear trend was performed by entering soyfood protein intake as
continuous variable in the logistic models. Because the recall of
usual diet is heavily influenced by current dietary intake
(Hankinson et al, 1998), we also performed analyses among those
who reported no change in soyfood intake one week before inter-
view, in order to minimize potential misclassification errors.
Further analyses were stratified by menopausal status, BMI, WHR
and ER/PR status. The 75th percentile of BMI and WHR among
controls was used as a cut-point in these stratified analyses, as
Chinese women are, in general, thinner than Caucasian women.
All statistical tests were based on 2-sided probability. 
RESULTS 
Table 1 shows comparisons of cases and controls on demographic
and lifestyle risk factors of breast cancer, including dietary factors.
Data are presented for all subjects and for those who reported no
recent change in soyfood intake, between which there were no
appreciable differences. For both groups, compared to controls,
cases were slightly older, had earlier menarcheal age, later
menopausal age, later age at first live birth, and ate more meats
and fish. Compared to controls, cases were more likely to have a
higher education, a family history of breast cancer among first-
degree relatives, a history of breast fibroadenoma, a higher BMI,
or WHR, and were less likely to exercise regularly. All the above
variables were considered potential confounders and adjusted for
in subsequent analyses. No significant differences between cases
and controls were observed for parity, months of breast feeding,
alcohol consumption, use of oral contraceptives, hormone replace-
ment therapy, measured height, and usual intake of total energy,
fruits and vegetables and fat. 374 Q Dai et al 
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Summarized in Table 2 are the intakes of soyfoods, soy protein
and isoflavones among the control group. Mean intakes for soy
protein and isoflavone were 72.1 g week–1 and 286.3 mg week–1,
respectively. Processed soy products other than tofu accounted for
more than half of total soy protein intake. Tofu, the second most
commonly consumed soy product in the population accounted for
19.4% of soy protein intake. Soy protein was positively correlated
with intake of meats (r = 0.11, P < 0.001), fish (r = 0.30, P <
0.001), and fruits and vegetables (r = 0.27, P < 0.001), although
the correlation was only weak to moderate (data not shown in
tables). These dietary variables were also adjusted in data
analyses. 
The intake levels of soyfoods were high in Shanghai women,
with 96.2% cases and 96.8% controls reporting soyfood consump-
tion at least once a week. After adjusting for total energy and other
potential confounders, the OR for breast cancer was 0.78 (95%
CI: 0.52–1.16) for regular soyfood consumers (at least once a
week) compared to those who ate soyfoods less often than weekly
(Table 3). Among regular soyfood eaters, a 30% (95% CI =
0.43–1.02) reduced risk appeared among women with the highest
soy protein intake but the test for trend was not significant (P =
0.10). A similar pattern of associations was observed among
women who reported no recent change in soyfood intake, although
the inverse association was more pronounced (P for trend, 0.02).
Analyses according to the decile distribution of soy protein intake
among controls showed a similar pattern of inverse associations,
and the ORs were statistically significant among women with the
highest intake of soy protein. The inverse association was
observed in both pre-and postmenopausal women (data not
shown). 
Table 1 Comparison of cases and controls on selected demographics and breast cancer risk factors, the Shanghai Breast Cancer Study, 1996–1998 
All subjects Subjects with no dietary changee 
Casesa Controlsa P value Casesa Controlsa P value
(n = 1459) (n = 1556) (n = 724) (n = 1015)
Age 47.8±8.0 47.2±8.8 0.03 47.8±8.04 7.0±8.5 0.06 
Education (%) 
No formal education 3.6 5.5 3.0  4.7 
Elementary school 8.5 8.4 8.7 8.2 
Middle and high school 74.3 75.4 74.5  77.1 
College and higher 13.6 10.7 0.01 13.8  10.0 0.04 
Breast cancer in first degree relatives (%) 3.7 2.4  0.05 3.4 2.2 0.10 
Ever had breast fibroadenoma (%) 9.6 5.0  <0.01 10.2 5.4 <0.01 
Regular alcohol drinke r(%) 4.0 4.1 0.99  4.1 4.0 0.92 
Ever used oral contraceptives (%) 21.9 20.9  0.51 20.9 20.4 0.77 
Ever used hormone replacement therapy (%) 2.9 2.7  0.76 2.2 2.9 0.40 
Exercised regularly (%) 18.8 25.2 <0.01  17.4 22.8 <0.01 
Height (cm) 158.9±5.10 158.5±5.37  0.07 158.8±4.90 158.6±5.46 0.39 
Body mass index 23.5±3.4 23.1±3.4  <0.01 23.6±3.5 23.2±3.3  0.02 
Waist-to-hip ratio 0.81±0.06 0.80±0.06  <0.01 0.81±0.05  0.80±0.06 <0.01 
Nulliparous (%) 5.1 3.9 0.13 4.8 3.8  0.32 
Number of live birthsb 1.5±0.85 1.5±0.86 0.54  1.5±0.81 1.5±0.82 0.55 
Age at first live birthb (years) 26.8±4.2 26.2±3.9 <0.01 25.6±7.1  25.3±6.2 0.30 
Months of breast feedingc 15.1±13.1 15.9±14.0 0.81 11.3±12.3  12.0±12.8 0.23 
Menarcheal age (years) 14.5±1.6  14.7±1.7 <0.01 14.4±1.6  14.7±1.7 <0.01 
Menopausal aged(years) 48.1±4.6 47.5±4.9 0.02 47.8±4.6  47.2±5.1 0.21 
Energy intake (kcal/day) 1865.9±464.2  1839.9±464.2 0.12 1816.3±446.3  1803.2±445.5 0.95 
Total fat intake (g/day) 36.3±17.4  35.3±16.2 0.08 34.5±16.1  34.6±15.5 0.90 
Total meat intake (g/day) 49.6±34.5  44.1±28.4 <0.01 47.3±30.8  45.8±27.2 0.03 
Total fruit and vegetable (g/day) 290.4±160.7  288.7±165.0 <0.78 302.1±166.5  289.9±157.6 0.21 
Total fish intake (g/day) 35.3±36.7 30.2±30.0 <0.01  33.4±30.6 29.1±26.6 <0.01 
Subjects with missing values were excluded from the analysis. aUnless otherwise specified, mean±SD are presented. bAmong women who had live births.
cAmong women who ever breast fed. dAmong menopausal women. eOut of 1104 cases and 1232 controls who completed the supplementary questionnaire
which was added to the study 7 months after the initiation of the study–see text. 
Table 2 Intake levels of soybean food and soy protein among controls in the Shanghai Breast Cancer Study,
1996–1998 
Mean±SD Median (25th, 75th percentile)  Protein equivalent
Mean±SD 
Soy foods (g/week) 
Total soyfood 947.8±889.0 654.5 (350.0, 1249.5) 
Soy milk 405.3±683.2 0 (0, 466.9)  7.0±12.6 
Tofu 223.3±241.5 186.9 (93.1, 373.1)  14.0±14.7 
Processed soy products other than tofu 156.8±534.8  93.1 (25.9, 233.1) 38.5±45.5 
Dry soybean seed 7.0±51.1 0 (0, 2.8)  2.1±17.5 
Fresh soybean 117.6±152.6 70.0 (30.8, 155.4)  8.4±10.5 
Soybean sprout 37.8±60.9 11.9 (0, 46.9)  1.4±2.8 
Soy protein (g/week) 72.1±70.7 56.0 (33.6, 90.3) 
Isoflavones (mg/week) 286.3±276.5  232.4 (130.9, 373.1) Soyfood intake and breast cancer risk 375
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Analyses were performed by ER/PR status of breast cancer and
stratified by BMI or WHR levels (Table 4). A 60% reduced risk
was observed for ER+/PR+ breast cancer among regular soy
consumers, and the test for trend was statistically significant (P for
trend, 0.05). This association was more marked among those who
reported no recent change in soyfood intake (P for trend, 0.004),
with an OR of 0.28 (95%CI = 0.13–0.57) observed in the highest
intake group. In contrast, no apparent association of soyfood
intake was observed for other groups of breast cancer cases
defined by ER/PR status. In analyses stratified by BMI level, a
substantially reduced risk (60–70%) of breast cancer was observed
for those who had a BMI of 25 or higher. This inverse association
was more evident among those who had no recent change in
soyfood intake (P for trend, 0.03) with an OR of 0.21 (95% CI
0.06–0.77) for the highest intake group. The risk was only slightly
reduced among regular soy consumers who had a low BMI. This
pattern of association suggests an interaction, although the tests for
multiplicative interaction were not statistically significant (P =
0.51 for all subjects; P = 0.14 for those who had no recent change).
The inverse association with soyfood intake also appears to be
stronger among women with a high WHR than those with a low
WHR, especially among women who reported no recent change in
soyfood intake. 
DISCUSSION 
The results of this large population-based case–control study
suggest that regular soyfood intake, particularly very high intake
of soyfoods, may be associated with a reduced risk of breast
cancer, particularly those positive for both ER and PR. The inverse
association was more evident among women who had a high BMI
than those who had a low BMI. These findings are consistent with
observations from in vitro and animal studies implicating potential
cancer inhibitory effects of soy and its constituents (Adlercreutz
and Mazur, 1997). 
The primary concern in this study is the possibility that potential
errors, both differential and non-differential, in assessing soyfood
intake may have biased results. The diets of cases may have
changed as a result of the cancer diagnosis and treatment (Willett,
1998). Current diet may also strongly influence the recall of usual
diet (Willett, 1998). Previous studies showed that breast cancer
cases who were receiving chemotherapy during the interview
reported a higher intake of micronutrients, macronutrients and
calories than cases who did not receive chemotherapy (Potischman
et al 1997, 1999). In our study, through a rapid case-reporting
system, we were able to interview nearly half of cases before they
received any treatment, and recent dietary changes for these
women were less substantial than those who had completed cancer
treatments. We found that there was no apparent association of
usual soyfood intake with breast cancer risk among women who
reported a recent increase in their soyfood intake (34% of cases
and 18% of controls). It is likely that some cases may have
increased their soyfood intake after breast cancer diagnosis and
treatment, and the recent dietary change may have affected the
recall of usual diet in some patients. Such a recall bias may have
biased the true inverse association towards the null in the analysis
of all subjects combined. Non-differential errors are a concern in
epidemiologic studies. This error may be particularly significant
among those who reported a recent dietary change, an indication
of unstable dietary practices. It has been shown that non-differen-
tial misclassification usually attenuates the true association. In
order to minimize the potential influence of measurement errors,
both differential and non-differential, we asked study subjects to
report their recent dietary practice and performed analyses on the
Table 3 Adjusted odds ratios (ORs) and 95% confidence intervals (Cls) for the association of breast
cancer with soy protein, the Shanghai Breast Cancer Study, 1996–1998 
Soy protein
All subjects Subjects without dietary change 
(g/week) Cases/controls OR* (95%CI) Cases/controls  ORa (95%CI) 
Analyses using occasional soyfood eaters as the reference group 
Occasionallyb 56/48 1.00 29/33 1.00 
Weekly 1403/1508 0.78 (0.52–1.16)  697/983 0.79 (0.47–1.33) 
≤35.0 322/378 0.76 (0.49–1.16)  174/255 0.81 (0.47–1.42) 
≤58.8 366/376 0.82 (0.54–1.26)  203/242 0.93 (0.54–1.63) 
≤91.0 388/374 0.88 (0.58–1.36)  188/247 0.89 (0.51–1.55) 
>91.0 327/380 0.66 (0.43–1.02)  132/239 0.56 (0.32–1.00) 
Trend test P = 0.10 P = 0.02 
Analyses using by decile distribution of soy protein intake among controls 
≤18.6 156/156 1.00 86/102 1.00 
≤28.7 122/157 0.74 (0.53–1.03)  67/116 0.61 (0.39–0.93) 
≤37.3 121/154 0.71 (0.51–1.00)  59/97 0.63 (0.40–0.99) 
≤47.0 170/157 0.98 (0.71–1.36)  104/103 1.05 (0.70–1.59) 
≤56.4 135/154 0.80 (0.58–1.12)  73/98 0.74 (0.48–1.15) 
≤68.9 188/157 1.14 (0.83–1.57)  90/105 0.93 (0.61–1.42) 
≤82.8 159/157 0.91 (0.66–1.27)  72/97 0.77 (0.50–1.20) 
≤102.7 157/153 0.89 (0.64–1.24)  78/108 0.73 (0.47–1.12) 
≤139.1 120/156 0.65 (0.46–0.92)  47/95 0.47 (0.29–0.76) 
>139.1 131/155 0.66 (0.46–0.95)  50/95 0.46 (0.28–0.75) 
Trend test 0.28 0.02 
aAdjusted for age, education, first degree family history of breast cancer, history of breast fibroadenoma,
waist-to-hip ratio, age at menarche, physical activity, birth of ³ 1 child, age at first birth, menopausal status,
age at menopause, intake of meats, fish, and total energy. bRefers to those who ate soyfood less than once
per week. 3
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Table 4 Adjusted odds ratios (ORs) and 95% confidence intervals (Cls) for the association of breast cancer with soy protein by ER/PR, BMI, WHR status, the Shanghai Breast Cancer Study, 1996–1998 
Subjects with no soyfood intake change  – Soy protein 
All subjects – Soy protein intake by quartile (g/week) intake by quartile (g/week)
<Weekly Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
ER/PR status
ER+/PR+ 504/1556 1.00 0.51 0.52  0.65  0.44  0.05  244/1016 1.00 0.44  0.49  0.56 0.28 0.004
(0.29–0.87) (0.30–0.89) (0.38–1.12) (0.25–0.78) (0.23–0.88) (0.25–0.97) (0.29–1.10) (0.13–0.57)
ER-/PR- 244/1556 1.00 0.94  1.30 1.09 0.78 0.91  130/1016 1.00 1.04 1.44  1.15 0.69  0.62 
(0.42–2.14) (0.58–2.91) (0.48–2.47) (0.33–1.81) (0.34–3.23) (0.47–4.40) (0.37–3.58) (0.21–2.25)
ER+/PR- or ER-/PR+ 208/1556  1.00 1.60  1.68   1.72  1.58  0.41  102/1016 1.00 1.22  1.17 0.97  0.75  0.43 
(0.55–4.67) (0.58–4.90) (0.59–5.02) (0.53–4.66) (0.34–4.37) (0.32–2.23) (0.26–3.58) (0.20–2.88)
BMI (by 75th percentile) 
BMI<25 1016/1154 1.00 0.86  0.97 0.96 0.76 0.49  495/751 1.00 1.04 1.17  1.05 0.81  0.28 
(0.53–1.38) (0.60–1.56) (0.60–1.55) (0.46–1.25) (0.55–1.98) (0.62–2.23) (0.55–2.00) (0.41–1.59)
BMI³25 443/402 1.00 0.34  0.34 0.45 0.30 0.15  231/265 1.00 0.35 0.43  0.45 0.21  0.03 
(0.11–1.06) (0.11–1.04) (0.15–1.39) (0.10–0.94) (0.10–1.25) (0.12–1.54) (0.13–1.59) (0.06–0.77)
WHR (75th percentile)
WHR<0.84 1021/1167 1.00 0.80  0.81 0.86 0.72 0.29  521/766 1.00 0.99 0.99  1.01 0.73  ) 0.12 
(0.49–1.30) (0.50–1.33) (0.53–1.41) (0.43–1.19) (0.53–1.83) (0.53–1.85) (0.54–1.89) (0.38–1.41)
WHR³0.84 438/389 1.00 0.75  0.96 1.07 0.61 0.20  205/250 1.00 0.55 1.02  0.83 0.35  0.12 
(0.31–1.86) (0.39–2.35) (0.44–2.61) (0.25–1.51) (0.15–2.11) (0.27–3.82) (0.22–3.12) (0.09–1.34)
Adjusted for age, education, first degree family history of breast cancer, history of breast fibroadenoma, waist-to-hip ratio, age at menarche, physical activity, birth of ³ 1 child, age at first live birth, menopausal status,
age at menopause, intake of total meats, total fish, and total energy. 
Stratifying
variables
No of
cases/
controls
P for
trend
No of
cases/
controls <Weekly
P for
trendsubset of participants who reported no recent dietary change. As
expected, the inverse association with soyfood intake was more
evident in this group of women than all subjects combined. This
finding points to the importance of controlling measurement errors
in epidemiologic studies and suggests that null associations
observed in epidemiologic studies, particularly case–control
studies in which cases are interviewed several months after cancer
diagnosis, should be interpreted with caution. 
The inverse association between soyfood intake and breast
cancer risk is supported by findings from ecological studies and a
large body of cell culture and animal experiments (Adlercreutz and
Mazur, 1997). Results from previous analytical epidemiologic
studies, however, are few and inconsistent (Lee et al, 1991, 1992;
Hirose et al, 1995; Yuan et al, 1995; Wu et al, 1996, 1998; Witte 
et al, 1997; Hirayama, 1990; Greenstein et al, 1996; Key et al,
1999). A weak but statistically non-significant inverse association
was reported in 3 cohort studies (Hirayama, 1990; Greenstein et al,
1996; Key et al, 1999) and 2 case–control studies (Hirose et al,
1995; Witte et al, 1997). Only 2 studies have reported a statisti-
cally significant inverse association with soyfood intake, but
neither evaluated potential modifying effects of BMI, WHR, and
ER/PR status (Lee et al, 1991; Wu et al, 1996). The findings of our
study are inconsistent with an earlier study conducted in Shanghai
(Yuan et al, 1995) in which the FFQ included only soymilk, tofu
and vegetarian chicken (a soy product) with a total estimated soy
protein intake of 3.5 g day–1 (Yuan et al, 1995). This level is only
about one-third of the total soy protein intake reported in the
current study (Table 2) in which tofu accounted for only 4.3% of
the between-person variation in total soy protein intake in
Shanghai, implying that soyfood intake in the previous Shanghai
study was underestimated. 
Soyfood intake is substantially lower in the US population
(Greenstein et al, 1996; Wu et al, 1998), where choices of
soyfoods are limited and tofu is usually the major provider of soy
protein. No previous studies were specifically designed to investi-
gate the association of soyfood intake with breast-cancer risk, and
none of the dietary instruments was formally validated for
measuring soyfood intake. Only one study used soy protein as a
measurement of total soyfood intake (Yuan et al, 1995). Some of
these limitations may account for the inconsistent findings
reported from previous studies. 
The Shanghai Breast Cancer Study was designed specifically to
test the hypothesis that soyfood intake reduces the risk of breast
cancer. The questionnaire included over 90% of the common
soyfoods consumed by Shanghai residents based on the results
from a 24-hour dietary recall study in a random sample of
Shanghai residents (Satia et al, 1999). In a recently completed vali-
dation study of about 200 Shanghai women with 24 days (twice a
month) of 24-hour dietary recalls, we found that the intake level of
soy protein derived from the FFQ was correlated well with that
derived from the 24-hour dietary survey (r = 0.49, P < 0.001).
Consumption of soyfoods is a personal dietary preference, and
intakes for most individuals are likely to be relatively stable over
time, particularly in Shanghai, an area with an abundant supply of
soyfoods. Using a subset of the control group in the Shanghai
Breast Cancer Study, we found a clear dose–response relationship
between usual soyfood protein intake derived from the FFQ and
the excretion rate of isoflavonoids in an overnight urine sample
(Chen et al, 1999), providing additional assurance that our dietary
questionnaire is valid in capturing usual soyfood intake in the
Shanghai population. We also found that breast cancer cases had a
substantially low-excretion of urinary isoflavonoids than controls
in a small case–control study (Zheng et al, 1999). 
One puzzling finding of this study is a lack of an apparent
monotonic dose–response association between soyfood intake and
breast cancer among regular soy consumers in most analyses. Very
high doses of soy or soy protein were used in previous intervention
studies to evaluate potential beneficial effects (Duncan et al, 1999;
Lu et al, 2000; Pino et al, 2000). On the other hand, the majority of
analytical epidemiologic studies reported thus far used women
who consumed none or very low amount of soyfoods as the refer-
ence group (Hirayama, 1990; Lee et al, 1991; Hirose et al, 1995;
Greenstein et al, 1996; Wu et al, 1996; Witte et al, 1997; Key et al,
1999). Most soy isoflavonoids are excreted in urine within 96
hours after soyfood consumption (Kelly et al, 1995), indicating
that it requires women to eat soyfoods at least on a weekly basis to
maintain a relatively constant isoflavonoid level in their body. It is
possible that no additional beneficial effect may be seen with
increasing intake amount of soyfoods among regular (weekly) soy
eaters. An alternative explanation may be that the precise intake
levels of soyfoods cannot be measured optimally among women
who consumed high levels of soyfoods. This is less likely,
however, since as noted above, we have shown that the validity of
the FFQ in assessing usual soyfood intake is high. 
Our findings for a strong association of soyfoods with breast
cancer positive for both ER and PR and a potential modifying
effect of BMI are supported by previous in vivo and in vitro
studies (Adlercreutz and Mazur, 1997; Wagner et al, 1997). Soy
isoflavones have a diphenolic structure similar to that of oestro-
gens and have been shown to have a weak oestrogenic and anti-
oestrogenic activity in many in vitro and in vivo systems
(Adlercreutz and Mazur, 1997). The anti-cancer effects have been
suggested to be mediated through various mechanisms, including
competing with endogenous oestrogens in binding to the oestrogen
receptors and nuclear oestrogen-binding sites, decreasing blood
levels of oestrogens and free oestrogens by increasing SHBG, and
inhibiting important steroid biosynthetic enzymes (Adlercreutz
and Mazur, 1997). After the menopause, adipose tissue is the
major site for oestrogen synthesis and women with a high BMI
have an elevated level of endogenous oestrogens (Siiteri, 1987). A
number of studies have found that high BMI is associated with an
elevated risk of ER+ breast cancer (Potter et al, 1995). Body
weight and central obesity have also been associated with an
elevated level of insulin and insulin-like growth factors (IGFs)
(Pasquali et al, 1987; Seidell, 2000). Insulin resistance and an
elevated level of IGF-I have been shown to be associated with an
increased risk of breast cancer (Bruning et al, 1992). Oestradiol
may also work synergistically with IGFs in the aetiology of breast
cancer (Thorsen et al, 1992). In addition to anti-oestrogenic
effects, several recent animal studies have shown that soy protein
improves glucose tolerance and insulin sensitivity (Wagner et al,
1997). 
In summary, our study showed that regular soyfood intake,
especially at very high level, may be associated with a reduced risk
of breast cancer, particularly for those positive for ER and PR. The
potential protective effect may be more pronounced in women
with a high BMI. These findings were biologically plausible and
consistent with cancer-inhibiting effects of soy and its
constituents. Our finding, if confirmed, may have implications for
the primary prevention of breast cancer. 
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